Gamboge Resin Sustained-Release Tablet for Constant Drug Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a sustained-release formulation containing the acetone-extracted product of gamboge resin for medical applications.
Innovation Solution
A formulation comprising 25.00 wt% to 31.25 wt% of the acetone-extracted product of gamboge resin, combined with sodium lauryl sulfate, hydroxypropyl methylcellulose, microcrystalline cellulose, silicon dioxide, magnesium stearate, lactose, and dextrose, formulated into a tablet for oral administration, which gradually releases the drug over a 12-hour to 72-hour period.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If the acetone-extracted product of gamboge resin is administered conventionally, then the drug can be delivered to the patient, but the drug is released too quickly and cannot maintain a constant blood level over an extended period
Solution Approach 1:
The patent changes the physical and chemical parameters of the drug delivery system by formulating the acetone-extracted product into a sustained-release tablet with specific composition ratios (25-31.25 wt% active ingredient, 4-25 wt% sodium lauryl sulfate, 15.63-23.44 wt% hydroxypropyl methylcellulose, 6.25-13.38 wt% microcrystalline cellulose, 0.63-1.56 wt% silicon dioxide, 0.63-1.56 wt% magnesium stearate, 25-40.13 wt% lactose, and 5-7.81 wt% dextrose). This formulation controls the release rate to achieve at least 80% dissolution after 24 hours while maintaining constant blood levels.
2Duration of action of moving object
If the drug is released slowly over an extended period, then the duration of action is improved, but the dissolution rate may be insufficient to achieve therapeutic effectiveness
Solution Approach 1:
The patent optimizes the formulation parameters to balance sustained release with adequate dissolution. The specific composition including disintegrants and surfactants ensures that at least 80% of the drug dissolves within 24 hours, providing sufficient therapeutic effect while maintaining extended duration of action through controlled release kinetics.
Solution Approach 2:
The patent uses a composite formulation combining multiple excipients with the active ingredient. The combination of hydroxypropyl methylcellulose (viscosifying agent), microcrystalline cellulose (disintegrant), sodium lauryl sulfate (surfactant), lactose (filler), and dextrose (filler) creates a matrix that controls drug release while ensuring adequate dissolution rate for therapeutic effectiveness.
Data Source
Figure 1
Figure 2
AI summary
A sustained-release formulation includes, based on the total weight of the sustained-release formulation, 25.00 wt% to 31.25 wt% of an active pharmaceutical ingredient including an acetone-extracted product of gamboge resin, 4 wt% to 25 wt% of sodium lauryl sulfate, 15.63 wt% to 23.44 wt% of hydroxypropyl methylcellulose, 6.25 wt% to 13.38 wt% of microcrystalline cellulose, 0.63 wt% to 1.56 wt% of silicon dioxide, 0.63 wt% to 1.56 wt% of magnesium stearate, 25.00 wt% to 40.13 wt% of lactose, and 5.00 wt% to 7.81 wt% of dextrose.